Pre-clinical efficacy of a selective p38MAPK inhibitor in a model of comorbid Alzheimer/vascular pathology
Description: NARRATIVE Alzheimer’s disease pathology and cerebrovascular pathology are frequently found together in the brains of older people, and vascular damage increases the risk of dementia, but little is known about how these two pathologies interact and drive disease progression. Our project will use novel mouse models and a unique CNS-active drug candidate to test the idea that dysregulated inflammation in the brain, driven by the stress kinase p38aMAPK, worsens the pathological and cognitive outcomes and can be targeted for therapeutic intervention. These mechanistic/ translational studies are a key first step to understanding how to someday prevent or treat these prevalent CNS diseases that afflict a growing number of elderly individuals.
Funder: National Institute on Aging
Funding type: research
Funder scheme: RF1
Start date: 2019-08-15
End date: 2024-08-31
Investigator: LINDA J VAN ELDIK
Institution: UNIVERSITY OF KENTUCKY
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 6
Funder award ID: RF1AG064859
OpenAlex ID: G1220127626